Statements Author contributions HY: Writing review & editing, Writing original draft
Retatrutides Phase 2 monotherapy weight loss (~24.2% at 48 weeks) is numerically larger than cagrilintides (~10.8% at 26 weeks), but those come from different trials, durations, and doses, and cagrilintides strongest data are as the CagriSema combination
SCFAs play an important regulatory role on various immune cells, particularly those central to maintaining immune homeostasis and anti-inflammatory responses, by inhibiting HDAC
In plain words, it may move the balance toward make more, break less, depending on the setting and the dose
Extreme workouts arent necessarygentle routines are fine
The formulation described has not been reviewed by the FDA for safety or efficacy